• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

    0.4005 -0.0228 (-5.39%)
    Streaming Delayed Price Updated: 3:26 PM EST, Feb 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 63,494,703
    Open 0.3881
    Bid (Size) 0.4004 (4,300)
    Ask (Size) 0.4005 (7,900)
    Prev. Close 0.4233
    Today's Range 0.3560 - 0.4445
    52wk Range 0.3315 - 3.870
    Shares Outstanding 75,993,532
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    Check out the stocks that are attracting the most attention and driving market activity. ↗
    Via Chartmill

    Performance

    YTD
    -86.1%
    -86.1%
    1 Month
    -84.9%
    -84.9%
    3 Month
    -87.4%
    -87.4%
    6 Month
    -83.0%
    -83.0%
    1 Year
    -69.2%
    -69.2%

    More News

    Read More
    News headline image
    Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? ↗
    Via Stocktwits
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Exploring Gossamer Bio's Earnings Expectations ↗
    Via Benzinga
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio to Participate in Upcoming Investor Conferences
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio to Participate in Upcoming Investor Conferences
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    This Saia Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
    Via Benzinga
    News headline image
    Gossamer Bio to Present at Upcoming Investor Conferences
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream ↗
    Via Stocktwits
    News headline image
    Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
    From Gossamer Bio, Inc.
    Via Business Wire
    News headline image
    Earnings Scheduled For May 15, 2025 ↗
    Via Benzinga

    Frequently Asked Questions

    Is Gossamer Bio, Inc. - Common Stock publicly traded?
    Yes, Gossamer Bio, Inc. - Common Stock is publicly traded.
    What exchange does Gossamer Bio, Inc. - Common Stock trade on?
    Gossamer Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Gossamer Bio, Inc. - Common Stock?
    The ticker symbol for Gossamer Bio, Inc. - Common Stock is GOSS on the Nasdaq Stock Market
    What is the current price of Gossamer Bio, Inc. - Common Stock?
    The current price of Gossamer Bio, Inc. - Common Stock is 0.4005
    When was Gossamer Bio, Inc. - Common Stock last traded?
    The last trade of Gossamer Bio, Inc. - Common Stock was at 02/24/26 03:26 PM ET
    What is the market capitalization of Gossamer Bio, Inc. - Common Stock?
    The market capitalization of Gossamer Bio, Inc. - Common Stock is 30.44M
    How many shares of Gossamer Bio, Inc. - Common Stock are outstanding?
    Gossamer Bio, Inc. - Common Stock has 30M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.